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BMP-2 induces EMT and breast cancer stemness through Rb
and CD44
Peide Huang1,2,5, Anan Chen3,5, Weiyi He1,5, Zhen Li1, Guanglin Zhang1, Zhong Liu1, Ge Liu1, Xueting Liu1, Shuilian He1, Gang Xiao1,
Feicheng Huang4, Jan Stenvang2, Nils Brünner2, An Hong1 and Ju Wang1
Bone morphogenetic protein 2 (BMP-2) has been reported to facilitate epithelial-to-mesenchymal transition (EMT) and bone
metastasis in breast cancer xenograft models. To investigate the role of BMP-2 in the development of breast cancer stem cells
(BCSCs), and to further elucidate the mechanisms underlying its inﬂuence on breast cancer metastasis, we conducted a
comprehensive molecular study using breast cancer cell lines and clinical samples. Our results showed that downregulation of Rb
by BMP-2 was associated with ubiquitin-mediated degradation activated by phosphorylation of Rb via the PI3K/AKT signal pathway.
In addition, the Smad signaling pathways are implicated in upregulation of CD44 protein expression by BMP-2. It was suggested
that cross-talk exists between Rb and CD44 signaling pathways, as recombinant human BMP-2 (rhBMP-2) was found to regulate
CD44 expression partly through Rb signals. In clinical tissues, BMP-2 was positively and negatively correlated with CD44 and Rb
expression, respectively. Based on the in vitro and in vivo results, we have established an integrated mechanism by which rhBMP-2
induces EMT and stemness of breast cancer cells via the Rb and CD44 signaling pathways, which then contribute to breast cancer
metastasis. These ﬁndings may be helpful for developing new strategies for the treatment and prognosis of advanced breast
cancer.
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INTRODUCTION
Breast cancer is a leading cause of cancer deaths among women
worldwide, second only to lung cancer;1 metastasis is the main
cause for breast cancer related deaths.2,3
The concept that cancer stem cells (CSCs) drive cancer
formation and progression has recently gained attention. Studies
have shown that breast cancer stem cells (BCSCs, marked as
CD44+/CD24−) promote tumor progression and exhibit enhanced
invasive properties to favor distant metastasis in patients.4,5
Bone morphogenetic proteins (BMPs) are multifunctional
growth factors belonging to the TGF-β superfamily. BMP-2 was
reported to facilitate epithelial-to-mesenchymal transition (EMT)6
and promote the motility and invasiveness of breast cancer cells
in vitro and in mouse xenograft model.7,8 A recent study reported
that the BMP-2 pathway can be activated by pollutants exposure,
and contributes to stem cell transformation and breast cancer
initiation.9 However, the mechanisms by which BMP-2 promotes
EMT and breast cancer metastasis, and its relationship with BCSC
development, remain largely unknown.
Although EMT is a well-characterized process during normal
development, its role in cancer progression is controversial.10 Many
studies suggested that EMT occurs during the generation of cancer
stem cells within primary tumors capable of metastasis.11–13
However, in some cases, a partial EMT or MET (mesenchymal–
epithelial transition) is necessary, such as during differentiation and
formation of tubules in kidney development.14,15
Rb (retinoblastoma) is a well-known cancer suppressor that
initiates and maintains cell cycle arrest, modulates apoptosis, and is
essential for early embryonic development. Rb regulates cell growth
and differentiation by modulating the activity of transcription factors
such as E2F family members.16,17 Inactivation of Rb in the mouse
mammary epithelium induces aggressive and metastatic mammary
tumors with basal stem cell-like phenotypes.18
CD44, an alternatively spliced transmembrane protein, func-
tions as a receptor for hyaluronan, and act as the co-receptor for
multiple receptor kinases linked with breast cancer.19 CD44
expression is essential for maintenance of the cancer stem cell
phenotype.20
In this study, we investigated the role of BMP-2 in BCSC
development. We aimed to elucidate the mechanisms underlying
the inﬂuence of BMP-2 on breast cancer progression using
recombinant human BMP-2 (rhBMP-2). This is the ﬁrst study that
reveals an integrated mechanism behind the effect of BMP-2 on
cancer stem cell formation and breast cancer metastasis.
RESULTS
rhBMP-2 induced EMT-like transformation, enhanced the
migration/invasion ability of breast cancer cells in vitro, and
promoted lung metastases of breast cancer in vivo
To evaluate the activity of rhBMP-2 (R&D Systems, Minneapolis,
MN, USA), alkaline phosphatase (ALP) was used as a marker for
detecting rhBMP-2 activity. Various concentrations of rhBMP-2
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were used to induce the differentiation of mouse myoblast C2C12
cells into osteoblasts. Results showed that ALP activity reached the
maximum value at rhBMP-2 concentrations of 4–8 ng/ml (Figure
1Aa) (**Po0.01, n= 3). Therefore, 4 ng/ml was chosen as the
optimal dose of rhBMP-2 used to induce MCF-7 cells in
subsequent experiments. Results indicated that 4 ng/ml rhBMP-2
was able to activate Smad-dependent signaling pathways in
MCF-7 cells (Figure 1Ab).
BMP-2 level (compared with total cell protein) in MCF-7 cells
was measured via ELISA. Intracellular concentration of BMP-2 was
found to be 356.46 pg/mg, whereas extracellular BMP-2 concen-
tration was 499.59 pg/mg (Figure 1Ac, Supplementary Table S1).
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This showed that native BMP-2 protein was produced in MCF-7
breast cancer cells at relatively low levels.
To investigate the potential role of BMP-2 in breast cancer
development, we treated three breast cancer cell lines (MCF-7,
MDA-MB-231, and a mouse breast cancer cell line 4T1) with
rhBMP-2 for 24 h. We found that rhBMP-2 induced elongated
morphologic changes in all three breast cancer cell lines.
Especially in MCF-7 cell line, rhBMP-2 drove MCF-7 cells from a
paving stone sheet-like shape to ﬁbroblastic-spindle shape with
pseudopodia formation (Figure 1Aa), which was considered to be
a characteristic of EMT.21 This indicated that rhBMP-2 may
promote EMT of breast cancer cells. As actin cytoskeleton
reorganization is considered another characteristic of EMT,
we then used atomic force microscopy (AFM) and ﬂuorescence
microscopy to observe the structure of actin cytoskeleton
in rhBMP-2-induced MCF-7 cells. We found that rhBMP-2
promoted reorganization of the actin cytoskeleton in MCF-7 cells
(Figure 1Ad).
We then performed a wound-healing assay on rhBMP-2-
induced breast cancer cells and found that 4 ng/ml rhBMP-2
signiﬁcantly enhanced breast cancer cell migration into the
wound (Figure 1Aa–b). In addition, results from transwell invasion
assays demonstrated that the average numbers of rhBMP-2-
treated MCF-7 and 4T1 cells invading through the membrane
were signiﬁcantly increased compared to those in the control
group (Figure 1Ac). Therefore, rhBMP-2 treatment could enhance
both migration and invasion capabilities of breast cancer cells
in vitro.
To further investigate the effect of rhBMP-2 on breast cancer
in vivo, we generated a lung metastatic breast cancer model
by inoculating Balb/c mice with 4T1 murine breast cancer
cells via the caudal vein. As shown in Figure 1C, the number
of metastatic tumor nodes in the lung was signiﬁcantly higher
in mice treated with rhBMP-2 than in those treated with PBS.
This suggests that rhBMP-2 promotes breast cancer metastasis
in vivo.
rhBMP-2 induced differential expression of the genes associated
with tumor metastasis in MCF-7 breast cancer cells
To determine the molecular mechanisms underlying the effects of
BMP-2 on breast cancer cells, we used the RT2 Proﬁler PCR Array
(Qiagen, Hilden, Germany) to detect changes in the expression of
84 genes known to be associated with tumor metastasis
(Supplementary Table S2).
Differential expressions of the 84 genes in rhBMP-2-induced
MCF-7 and control cells were calculated (Supplementary Table S3).
We identiﬁed 26 genes that were either signiﬁcantly upregulated
(Fold difference41.2; P-valueo0.05) or downregulated (Fold
differenceo0.8; P-valueo0.05) (Figure 2A). The most upregulated
genes were CD44 and MMP11, whereas the most downregulated
genes were RB1 and CDH1 (E-cadherin). To further investigate the
relationship between the expression status of these four genes
and the metastatic phenotype of clinical breast cancer, we
analyzed the expression of these four genes in a data set
(available online, GSE10797) consisting of normal breast tissues
and invasive breast cancer samples. We found that expressions of
BMP-2 and CD44 were signiﬁcantly upregulated, whereas expres-
sions of RB1 and CDH1 (E-cadherin) were signiﬁcantly down-
regulated in invasive breast cancer (Figure 2B). This suggested
that the expression of these four genes is associated with
invasiveness of breast cancer cells.
Western blot was performed to determine whether rhBMP-2
could affect protein expressions of Rb, E-cadherin, and CD44. Rb,
and E-cadherin were downregulated in MCF-7 cells; CD44 was
upregulated following rhBMP-2 induction (Figure 2Aa). Similarly, in
MDA-MB-231 cells, which were considered more aggressive than
MCF-7 cells, Rb expression was downregulated upon rhBMP-2
induction (Figure 2Ab). As the 4T1 cell line was derived from
rodents, we did not perform the assay on these cells.
CD44 is a cell-surface glycoprotein involved in cell–cell
interactions, cell adhesion, and migration.22 Immunocytochemis-
try assays demonstrated that rhBMP-2 upregulated CD44 expres-
sion and induced the redistribution of cellular CD44 to the leading
edges and lamellipodia of MCF-7 cells (Figure 2D).
rhBMP-2 promoted Rb phosphorylation and degradation through
Smad-independent PI3K/AKT signaling pathways, and modulated
the migration ability of MCF-7 breast cancer cells
To explore the role of Smad-dependent signal pathways in
association with BMP-2 and Rb, we silenced Smad4 in MCF-7 cells
by speciﬁc Smad4 siRNA. We found that silencing of the Smad4
protein in MCF-7 cells did not affect rhBMP-2-induced down-
regulation of Rb (Figure 3Aab).
We then examined Smad-independent signal pathways, espe-
cially the PI3K/Akt signaling pathway. We found that rhBMP-2
signiﬁcantly increased the phosphorylation of Akt (473) and Rb
(Ser807/811), and downregulated the expression of Rb in MCF-7
cells (Figure 3Aab); no effect on AKT (308) was observed. Speciﬁc
inhibitors of PI3K (LY294002) and Akt (MK-2206) were used to
study the role of PI3K/Akt signaling on rhBMP-2-induced changes
in Rb expression. Results indicated that phosphorylation of
Akt (473) and Rb (Ser807/811) was signiﬁcantly decreased
when cells were pre-treated with LY294002 or MK-2206.
Figure 1. rhBMP-2 induced EMT-like transformation, enhanced migration/invasion ability of breast cancer cells in vitro, and promoted lung
metastases of breast cancer cells in vivo. (A) Activity assay of rhBMP-2. (a) C2C12 cells were induced with different concentrations of rhBMP-2(0,
0.5, 1, 4, 8, 16, 32 ng/ml) for 72 h, and ALP activity was detected by using the ALP substrate kit (Bio-Rad, USA). Data are displayed as means
± S.D. (**Po0.01, n= 3). (b) MCF-7 cells were induced with 4 ng/ml rhBMP-2 for 24 h, and Smad1/5/8 and p-Smad1/5/8 were detected by
western blot (*Po0.05, n= 3). (c) ELISA was performed to detect the expression level of BMP-2 in MCF-7 cells, and canonical plotting was
carried out. (B) rhBMP-2 induced EMT-like transformation and enhanced migration/invasion ability of breast cancer cells. (a–b) Human breast
cancer cell lines MCF-7 and MDA-MB-231, and a mouse breast cancer cell line 4T1, were induced with 4 ng/ml rhBMP-2 for 24 h. Morphological
changes and the numbers of migrating cells were determined using an inverted microscope (Olympus ix71). Data are shown as mean± S.D.
(**Po0.01, n= 3). (c) MCF-7 and 4T1 cells were inoculated into the upper surface of QCMTM 96-well plates, and were induced with 4 ng/ml
rhBMP-2 for 24 h. Cells invading through the membrane were stained and measured under 480/520-nm transmitted light. Values are
presented as mean± S.D. (*Po0.05, n= 3). (d) MCF-7 cells were induced with 4 ng/ml rhBMP-2 for 24 h, and the actin cytoskeletons were
observed under an atomic force microscope (a–f ) or a ﬂuorescence microscope (g–i). (C) 60 BALB/c female mice were randomly divided into
three groups (n= 20). Experimental groups were intravenously injected with 4T1 cells, whereas the un-injected group was set as blank control.
Mice in one of the experimental groups were treated daily with 20 μg rhBMP-2 via the tail vein for 21 days. The other two groups were treated
with PBS for 21 days. Animals were killed, and lung weight and the number of tumor nodules were measured. (a) Photos of lung lobe (upper
panels) and H&E staining of lung biopsy (lower panels) from control, 4T1 inoculated, and 4T1 inoculated rhBMP-2-treated mice. (b) Left:
average weight of lungs from control, 4T1 inoculated, and 4T1 inoculated rhBMP-2-treated mice. Values are presented as mean± S.D.
(**Po0.01, n= 20). Right: average number of lung metastasized colonies from control, 4T1 inoculated, and 4T1 inoculated rhBMP-2-treated
mice. Data are presented as mean± S.D., (*Po0.05, n= 3).
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Concomitant impairments in Rb downregulation were also
observed (Figure 3Aab).
Phosphorylation is known to trigger ubiquitination and
degradation of regulatory proteins in many important cell
signaling processes.23 Therefore, we used a cell permeable
inhibitor of ubiquitin-activating enzyme E1, PYR-41,24 to study
the phosphorylation and potential degradation of Rb (Figure 3A
e). We found that downregulation of Rb induced by rhBMP-2 was
signiﬁcantly impaired when cells were pre-treated with PYR-41.
This was correlated with reduced phosphorylation in Rb
Figure 2. rhBMP-2 induced differential mRNA expression of genes involved in tumor metastasis, and affected the expression and distribution
of proteins in breast cancer cells. (A) MCF-7 cells were induced with 4 ng/ml rhBMP-2 for 24 h, and the expression changes of 84 genes
associated with tumor metastasis were detected by Human Tumor Metastasis RT2 Proﬁler PCR Array. The 26 signiﬁcantly upregulated (fold
difference41.2; P-valueo0.05; indicated by the red bar) and downregulated genes (fold differenceo0.8; P-valueo0.05; indicated by the
blue bar) was shown. (B) Gene expression levels of (a) BMP-2, (b) RB1, (c) E-cadherin and (d) CD44 in invasive breast cancer and normal breast
tissues from the GSE10797 breast cancer data set; differences were assessed by the unpaired-Student’s t-test. (C) (a) MCF-7 cells were induced
with 4 ng/ml rhBMP-2 for 24 h; protein levels of Rb, E-cadherin, and CD44 were determined by western blot. Data are presented as mean± S.
D., (**Po0.01, n= 3). (b) MDA-MB-231 cells were induced with 4 ng/ml rhBMP-2 for 24 h; protein levels of Rb were determined by western
blot. Data are presented as mean± S.D., (**Po0.01, n= 3). (D) Distribution of the CD44 protein (arrow indicates CD44 protein) in control (a;
0 ng/ml rhBMP-2, 24 h) and rhBMP-2-induced (b; 4 ng/ml rhBMP-2, 24 h) MCF-7 cells.
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(Ser807/811) (Figure 3Af). This strongly suggested that phosphor-
ylation of Ser807/811 sites triggers the ubiquitination and
subsequent degradation of Rb. Our results suggested that
BMP-2 induces phosphorylation and ubiquitin-dependent degra-
dation of the Rb protein through a Smad-independent PI3K/Akt/
Rb signaling pathway.
To gain further insights into the relationship between Rb
protein levels and the migration capability of MCF-7 breast cancer
cells, we used speciﬁc siRNA to deplete Rb proteins in MCF-7 cells.
In addition, we constructed a pcDNA3.1-Rb over-expression
plasmid, which was used to transiently transfected MCF-7 cells.
A wound-healing assay was subsequently carried out to determine
Bone morphogenetic protein 2 and breast cancer
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changes in MCF-7 cell motility. We found that depletion and over-
expression of the Rb protein signiﬁcantly enhanced and weakened
the motility of MCF-7 cells, respectively (Figures 3B and C).
rhBMP-2 upregulated CD44 protein expression and promoted cell
motility and BCSC development via Smad-dependent and PI3K/
Akt-Rb signaling pathways
Similarly, we found that depletion of CD44 by si-CD44 signiﬁcantly
decreased the motility of MCF-7 cells, and neutralized the
stimulatory effect of rhBMP-2 (Supplementary Figures 1A–C). To
investigate the relationship between rhBMP-2 and CD44, we
silenced Smad4 in MCF-7 cells with 4 ng/ml rhBMP-2 for 24 h, and
found that upregulation of CD44 by rhBMP-2 was inhibited (Figure
4Aab). Upregulation of the CD44 protein may possibly be
mediated by the classical Smad signaling pathway. The Smad4
protein possesses a MH1 domain, which recognizes the
double-stranded DNA sequence motif 5′-CAGAC-3′ known as the
Smad-binding element (SBE).25 The promoter sequence of CD44
was found to harbor an SBE-rich region (−3090 to − 2705 bp,
Supplementary Table S4). We hypothesized that the Smad
complex may bind to these SBEs and regulate expression of
CD44. We therefore constructed a CD44 luciferase reporter system
(Figure 4Ac), and found that rhBMP-2 markedly enhanced CD44
promoter activity in MCF-7 cells, which was impaired by
interfering Smad4 expression (Figure 4Ad). This result demon-
strated again that the Smads complex may bind to the CD44
promoter and directly regulate rhBMP-2-mediated increase in
CD44 expression (Figure 4Ae).
To investigate whether stemness is enhanced following BMP-2
treatment, we quantiﬁed CD44+/CD24− populations in rhBMP-2
(4 ng/ml)-induced MCF-7 cells using the FACSCalibur ﬂow
cytometer. We found that the CD44+/CD24− cells induced by
rhBMP-2 showed a 4.8-fold increase compared with untreated
cells (Figure 4A a b). We also performed 3D tumor spheroid
formation assays to evaluate the effect of rhBMP-2 on proliferation
of BCSCs. We observed an increase in the average size of tumor
spheroids in the rhBMP-2 treatment group compared with in the
control group (Figure 4Aab). These results demonstrated that
rhBMP-2 promotes the development of CSCs in MCF-7 cells. In
addition, siSmad4 neutralized the rhBMP-2-induced upregulation
of CD44+/CD24− population in MCF-7 cells (Figure 4Aab), which
demonstrated that the stimulatory effect of rhBMP-2 on BCSC
development was mediated through the Smad signaling pathway.
To determine the relationship between Rb and CD44, we
assessed the level of CD44 in Rb- depleted MCF-7 cells by western
blot. Our results showed that CD44 expression was signiﬁcantly
upregulated in Rb-silenced cells compared with that in control
MCF-7 cells (Figure 4Aab). Further study showed that CD44
upregulation by rhBMP-2 was impaired when cells were pre-
treated with PI3K and AKT inhibitors (LY294002 and MK-2206)
(Figure 4Aab). These results suggested that expression of CD44
was partially regulated by PI3K/Akt-Rb signaling.
BMP-2 expression was inversely correlated with Rb expression,
and was positively correlated with CD44 expression in breast
carcinoma tissues
To determine the protein levels of BMP-2, Rb, and CD44 in breast
cancer tissues, we collected 40 breast carcinoma tissue samples
(classiﬁcation of the samples is shown in Supplementary Table S5),
and immunohistochemical analysis was performed.
The widely accepted German semi-quantitative scoring system
used to quantify staining intensity and area was used.26 Breast
tumor samples were divided into three categories based on BMP-2
levels, and were deﬁned by their expression scores as low (0–4),
medium (5–8), or high (9–12).
By analyzing the immunohistochemical images and immunor-
eactive scores of BMP-2, CD44, and Rb proteins in each sample, we
conﬁrmed that BMP-2 expression was positively correlated with
CD44 expression in the breast carcinoma cohort (Figures 5a and b,
Supplementary Figure 2). In contrast, BMP-2 expression was found
to be negatively correlated with Rb expression (Figure 5a and c;
Supplementary Figure 3).
DISCUSSION
BMPs are highly conservative functional proteins belonging to the
transformation growth TGF-β superfamily. They were originally
identiﬁed based on their ability to facilitate bone formation at
extra-skeletal sites. However, for the last decade, they have been
extensively studied in several cancers.27–30 Functional studies
revealed contradictory roles of BMPs in both cancer promotion
and inhibition.31–34 Especially in breast cancer, different BMP
ligands have been shown to decrease as well as increase cancer
cell growth and migration.35 In our previous study, we showed
that BMP-2 inhibited cancer cell growth both in vitro and in vivo
by inducing G1 arrest and apoptosis in MDA-MB-231 and MCF-7
human breast cancer cell lines.36 Here, we further investigated the
mechanism underlying the inﬂuence of BMP-2 on breast cancer
metastasis through a comprehensive molecular study using breast
cancer cell lines and clinical breast cancer samples. Our results
indicated that BMP-2 promoted EMT and migration/invasion of
breast cancer cells. In addition, it was shown to favor lung
metastasis in vivo, which was in agreement with several other
recent studies.6–8 A possible interpretation to the dual roles of
BMP-2 is that in the early stages of breast cancer development,
BMP-2-induced apoptosis plays a dominant role owing to low
Figure 3. rhBMP-2 promoted Rb phosphorylation and degradation through Smad-independent PI3K/AKT signaling pathway, and affected the
migration ability of MCF-7 breast cancer cells. (A) (a, b) MCF-7 cells transiently transfected with native control siRNA (siNC) or Smad4 siRNA for
24 h. Transfected and non-transfected MCF-7 cells were induced with 4 ng/ml rhBMP-2 for 24 h, and expression levels of Smad4 and Rb were
determined by western blot. Data are presented as mean± S.D. (**Po0.01, *Po0.05, n=3). (c, d) PI3K and AKT inhibitors, LY294002 and
MK-2206, were added to MCF-7 cells 1 h before rhBMP-2 induction. MCF-7 cells were induced with 4 ng/ml rhBMP-2 for 24 h. Relative protein
levels were analyzed by western blot. Data are presented as mean± S.D. (***Po0.005, **Po0.01, *Po0.05, n= 3). (e, f ) Ubiquitin-activating
enzyme E1 inhibitor, PYR-41, was incubated with MCF-7 cells for 30 min prior to the 24- h rhBMP-2 (4 ng/ml) induction. Rb and phosphorylated
Rb were analyzed by western blot; data are presented as means± S.D. (***Po0.005, **Po0.01, *Po0.05, n= 3). (B) (a) Wound-healing assay was
performed to evaluate the migration of MCF-7 cells transiently transfected with siRb, negative control siRNA (siNC), or the transfection reagent
(lipo2000) for 24 h. (b) Real-time PCR was performed to examine the targeting efﬁciency of Rb stealth RNAi (siRNA). The most effective siRNA siRb-
1 was chosen for the following experiments. Values presented as mean± S.D., (**Po0.01, n=3). (c) Migration abilities of MCF-7 cells transiently
transfected with siRb-1, negative control siRNA, or the transfection reagent (lipo2000). The average number of cells migrated into the wound was
shown for each group. Values are presented as mean± S.D. (**Po0.01, n= 3). (C) (a) pcDNA3.1-Rb over-expression plasmids were constructed
using an Endo-free plasmid mini kit I. MCF-7 cells were transfected with the pcDNA3.1 vector, the transfection reagent, or the pcDNA3.1-Rb
plasmids at 37 °C for 24 h. Cells were induced with 4 ng/ml rhBMP-2 for another 24 h, and wound-healing assay was performed to detect
variations in migration of MCF-7 cells. (b) Rb protein levels in non-transfected control, vector-transfected, reagent-transfected, and Rb plasmid
transfected groups, as analyzed by western blot. (c) Numbers of migratory cells in non-transfection control, vector-transfected, reagent-
transfected, and Rb plasmid transfected groups. Values are expressed as mean± S.D. (**Po0.01, n=3).
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number of tumor cells; as the tumor continues to develop, EMT
and stemness induced by rhBMP-2 have more signiﬁcant roles
than programmed tumor cell deaths. Therefore, the timing of
BMP-2 induction may lead to differential outcomes in tumors,
such as death or metastasis.
Notably, rhBMP-2 promoted the formation of tumor spheroids
and increased the population of CD44+/CD24− cells in MCF-7
breast cancer cells (Figure 4B) in this study. These observations
suggest that rhBMP-2 enhances the stemness of breast cancer
cells. BMP signaling was thought to have important roles in
regulating the survival and maintenance of CSCs,37,38 and the
contributions of BMP-2 to the development of CSCs in different
cancers are debated.34,39–42 Although BMP-2 was shown to inhibit
CSC tumorigenicity in osteosarcoma and renal cell carcinoma,34,39
Bone morphogenetic protein 2 and breast cancer
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in support of our ﬁnding, BMP-2 was also reported to promote
CSC formation in colon and ovarian cancers.41,42 Interestingly, in
another study, BMP-2/7 heterodimer was shown to inhibit CSC
subpopulations and onset of bone metastases.40 Therefore, the
relationship between BMP signaling and CSC remains controver-
sial. One possible explanation may be that the BMP-2/7
heterodimer introduces a competitive effect on other BMP signals,
thus disrupting regulatory processes of CSC formation and
metastases. Nevertheless, the contradictory reports also unveiled
the complexities behind the signaling mechanisms of BMP-2 in
EMT and CSC formation. As a result, there is an imperative need to
further study the signaling mechanisms underlying the effect of
BMP-2 on EMT and BCSC formation.
We investigated the mRNA and protein expressions of 84 genes
known to be involved in tumor metastasis in rhBMP-2-treated
MCF-7 cells; rhBMP-2 signiﬁcantly downregulated Rb and E-cad-
herin and upregulated CD44 expression in MCF-7 cells (Figure 2).
Rb is a well-known tumor suppressor. It inhibits transcription of
genes required for the G1-S phase, which results in cell cycle
arrest.16 It is usually inactivated by mutations in several human
cancers.43,44 Furthermore, functional loss of the Rb gene has been
shown to contribute to aggressive tumor phenotypes and induce
EMT in breast cancer.18,21,45 Arima et al.21 showed that Rb can bind
to the E-cadherin promoter in conjunction with AP-2α. Knock-
down of Rb by small interfering RNA in MCF-7 breast cancer cells
resulted in deregulation of E-cadherin, disruption of cell–cell
adhesion, and induction of mesenchymal-like phenotypes. Our
study further showed that deregulation of Rb, E-cadherin, and
disruption of cell–cell adhesion was induced by rhBMP-2 in MCF-7
cells. These ﬁndings suggested that E-cadherin is downregulated
by rhBMP-2 via depletion of Rb, and contributes to EMT. Our study
highlighted the crucial role of Rb in BMP-2 signaling during EMT
induction.
We also found that BMP-2 downregulated Rb protein through a
Smad-independent PI3K/AKT signaling pathway in breast cancer
cells. Results indicated that Rb was phosphorylated and subjected
to ubiquitin-dependent degradation, which was mediated by the
PI3K/Akt signaling pathway (Figure 3A a–f). Consistent with our
ﬁndings, phosphorylation has been shown to be a common
strategy that triggers the ubiquitination and degradation of
certain proteins in many important cell processes.23,46 Different to
our ﬁnding of phosphorylation of Rb on Ser807/811, phosphor-
ylation of Rb on Ser567 had been reported to trigger ubiquitin-
dependent degradation of Rb in melanoma cell though it was
activated by p-38 signal pathways, and resulted in cell apoptosis.47
Moreover, the PI3K/Akt signaling pathway has been shown to
activate phosphorylation of Rb, leading to disassociation of the
Rb-E2F complex and cell proliferation but they only speculated
the degradation of Rb caused by proteasome-mediated
degration,47–49 so we ﬁrstly demonstrated this mechanism to
down-regulate Rb by rhBMP-2 to promote metastasis in
MCF-7 cells.
CD44 is a transmembrane glycoprotein widely expressed in
physiological and pathological systems,22 and is associated with
tumor metastasis and BCSCs.4,5,50 According to recent studies, the
cleaved intracellular domain of CD44 (CD44ICD) activates stem-
ness factors such as Nanog, Sox2, and Oct4, and contributes to
tumorigenesis of breast cancer, which may explain the effect of
CD44 on BCSC maintenance.51 In this study, we showed that
BMP-2 upregulated CD44 expression and promoted CSC devel-
opment in breast cancer cells. On one hand, our results showed
that rhBMP-2 caused CD44 to localize in the leading edges and
lamellipodia of MCF-7 cells (Figure 2D), which was consistent with
Kim et al.52 Their study showed that the formation of F-actin-
positive cellular protrusions such as ﬁlopodia and invadopodia,
which are essential for initiation and progression of metastasis,53
was CD44-dependent. On the other hand, rhBMP-2 upregulated
the expression of CD44 proteins and promoted the stemness of
breast cancer cells (Figure 4B). These ﬁndings indicate that CD44
enables breast cancer cells to disseminate from the primary tumor,
and promotes their ability to self-renew and colonize to
distant sites.
We then sought to further decipher the signaling pathways
between BMP-2 and CD44. Smad proteins are the central
mediators of the TGF-β family of signaling molecules. Although
the R-Smads, Smad1/5/8, are phosphorylated following activation
by BMP receptors, the Co-Smad, Smad4, are recruited and
combined with p-Smad1/5/8; the fully assembled complex then
acts as a transcription factor to regulate the expression of
target genes.
Through Smad4 siRNA silencing and the CD44 promoter
luciferase reporter system, we found that rhBMP-2 upregulated
CD44 expression in MCF-7 cells via binding of Smad4 to the
promoter sequence of CD44 (Figure 4Aa–e), which contains a SBE-
rich region (Supplementary Table S4).
Our study further showed that upregulation of CD44 was
partially caused by activation of the PI3K/Akt pathway and
reduction in Rb protein level (Figure 4C). This result was consistent
Figure 4. rhBMP-2 upregulated CD44 protein expression, and promoted cell motility and BCSC development via the Smad and PI3K/Akt-Rb
signaling pathway. (A) (a, b) MCF-7 cells were transiently transfected with native control siRNA (siNC) or Smad4 siRNA for 24 h, after which
they were induced with 4 ng/ml rhBMP-2 for 24 h. Smad4 and CD44 protein expressions were analyzed by western blot. Values are expressed
as mean± S.D. (**Po0.01, *Po0.05, n= 3). (c, d). CD44 reporter plasmid was constructed by adding the CD44 promoter sequence (3135 bp)
into a pGL3-basic luciferase reporter vector. MCF-7 cells were transfected with the pGL3-basic control plasmid, the CD44 reporter plasmid, the
Renilla luciferase expression construct, siNC, or siSmad4 for 24 h. The CD44 reporter, CD44 reporter plus siNC, and CD44 reporter plus siSmad4
transfected cells were induced by 4 ng/ml rhBMP-2 for 24 h. Activities of CD44 were measured by dual luciferase assay (Promega). Values are
expressed as mean± S.D., (***Po0.005, n= 3). (e) Schematic diagram showing rhBMP-2-induced upregulation of CD44 via binding of Smad4
to the promoter of CD44. (B) (a) MCF-7 cells (103 cells/ml) were mixed with 5% Matrigel medium at a 1:1 ratio, and were inoculated into 24-well
plates. Cells were induced by different concentrations of rhBMP-2 (0, 4, 8 ng). All cell cultures were incubated at 37 °C and 5% CO2 for 3 days.
Tumor spheres were observed under an inverted microscope. Representative photos of MCF-7 tumor spheres from the three groups are
shown. (b) Diameters of 30 randomly chosen tumor spheres in each group are displayed in boxplots (n= 30, differences between groups were
assessed by the Student’s t-test). (c, d). MCF-7 cells were divided into three groups (blank control, rhBMP-2-induced, siSmad4 rhBMP-2-
induced). Cells in the siSmad4 rhBMP-2-induced group were transiently transfected with Smad4 siRNA for 24 h. Cells in both the rhBMP-2-
induced group and siSmad4 rhBMP-2-induced groups were induced with 4 ng/ml rhBMP-2 for 24 h. The CD44+/CD24- cell population in each
group was detected via ﬂow cytometry. Data are expressed as mean± S.D., (**Po0.01, n= 3). (C) (a) Expressions of Rb and CD44 in MCF-7 cells
were evaluated by Western blot following siRNA-mediated Rb silencing. (b) Relative expression levels of Rb and CD44 in normal (NC) and Rb
interfered (siRb1, siRb2) cells. Values are expressed as mean± S.D., (*Po0.05, n= 3). (c–d) PI3K and AKT inhibitors, LY294002 and MK-2206,
were added to MCF-7 cells 1 h prior to rhBMP-2 induction. MCF-7 cells were then induced with 4 ng/ml rhBMP-2 for 24 h (this experiment
was the same as Figure 3Ac and the same lysates were used to detected protein levels of Rb, p-Rb, AKT, p-AKT, β-actin, Histone3, as well as
CD44 by western blot). Relative protein expressions were determined by western blot. Values are expressed as mean± S.D. (**Po0.01,
*Po0.05, n= 3).
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with that of a recent study, which showed that CD44 expression
was required for collective motility and metastatic progression
initiated by loss of Rb function in breast cancer.52 This suggested
that cross-talks between Rb and CD44 pathways are required for
BMP-2-dependent EMT and development of BCSCs.
In support of this conclusion, our immunohistochemical assays
performed in clinical breast cancer samples also shown an inverse
correlation between the expression levels of BMP-2 and Rb and a
positive correlation between BMP-2 and CD44 (Figures 5a–c).
In summary, this is the ﬁrst study demonstrating that BMP-2
promotes EMT and breast cancer stemness via Rb and CD44
signaling pathways (Figure 6). We found that Rb and CD44 are two
key mediators in the rhBMP-2 signaling pathway. In addition, both
PI3K/AKT and Smad signaling are implicated in the regulation of
Rb and CD44 expression. Our in vitro and in vivo ﬁndings highlight
the crucial roles of BMP-2, Rb, and CD44 in breast cancer
metastasis, which may provide new strategies for the treatment
and prognosis of advanced breast cancer.
MATERIALS AND METHODS
Cell lines, cultures, and treatments
The human breast cancer cell lines MCF-7 and MDA-MB-231, mouse
myoblasts cell line C2C12, and mouse mammary carcinoma cell line 4T1
Figure 5. BMP-2 expression was inversely correlated with Rb expression and positively correlated with CD44 expression in the breast
carcinoma cohort. (a) Immunohistochemistry was performed to detect expressions of BMP-2, Rb, and CD44 in 40 breast cancer tissue samples.
Samples were categorized into three groups based BMP-2 levels deﬁned by their expression scores: low (0–4), medium (5–8), and high (9–12).
Representative images show the expression of Rb and CD44 in samples belonging to the low, medium, and high BMP-2 groups. (b) Plot
demonstrating positive correlation between BMP-2 and CD44 expression in our breast carcinoma cohort. CD44 expression in each group was
also deﬁned by their scores. The asterisks represent extreme outliers, whereas the dots stand for mild outliers. (c) Plot demonstrating negative
correlation between BMP-2 and Rb expression in our breast carcinoma cohort. Rb expression in each group was also deﬁned by their scores.
The asterisks represent extreme outliers, whereas the dots stand for mild outliers.
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were obtained from the American Type Culture Collection (ATCC, USA).
MCF-7 and C2C12 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (Gibco, ThermoFisher Scientiﬁc, Waltham, MA, USA)
supplemented with 10% fetal bovine serum (FBS) (Gibco). MDA-MB-231
cells and 4T1 cells were cultured in RPMI 1640 (Gibco) with 10% FBS. All
cell lines were grown in 5% CO2 at 37 °C in a humidiﬁed incubator.
Activity assay of rhBMP-2
C2C12 cells were seeded in 24-well plates at an initial density of 5 × 104
cells/well, and were cultured overnight. Following a 12-h starvation period,
cells were induced with different concentrations of rhBMP-2(0, 1, 4, 8, 16,
32 ng/ml) for 72 h. An ALP substrate kit (Bio-Rad, Hercules, CA, USA) was
used to determine activity of rhBMP-2.
Lung metastasis of breast cancer in Balb/c mice
Balb/c mice (4–5 weeks old) were obtained from the Experimental Animal
Research Centre of Zhongshan University, and were maintained in its SPF
laboratory. Female Balb/c mice (60), 4–6 weeks of age, were randomly
divided into three groups (n=20). Two groups were intravenously injected
with 4T1 cells, and were deﬁned as experimental groups, whereas the un-
injected group was set as blank control. Mice in one of the experimental
groups were treated daily with 20 μg rhBMP-2 via the tail vein for 21 days;
the other two groups were treated with PBS for 21 days. After animals were
sacriﬁced, lung tumor nodules were counted, and lung tissues were ﬁxed
in formalin.
3D spheroid formation in MCF-7 cells
Matrigel (60–100 μl) was embedded into the bottom of a 24-well plate to
form a 0.5–1-mm thick solidiﬁed gel layer. MCF-7 cells were dissociated
and diluted to a density of 103 cells/ml. Complete medium containing 5%
Matrigel was mixed with the cell suspension at a 1:1 ratio and seeded onto
a 24-well plate. Cell samples were divided into three groups, which were
induced by different concentrations of rhBMP-2 (0, 4, 8 ng/ml). All cell
cultures were incubated at 37 °C and 5% CO2 incubator for three days,
after which the tumor spheres were observed under an inverted
microscope. The diameters of 30 randomly chosen tumor spheres were
measured for each group.
Flow cytometry assay
MCF-7 cells were cultured in six-well plates, and were divided into three
groups (blank control, 4 ng/ml rhBMP-2-induced and siSmad4 4 ng/ml
rhBMP-2-induced). Cells in the siSmad4 4 ng/ml rhBMP-2-induced group
were transiently transfected with Smad4 siRNA for 24 h. Both the 4 ng/ml
rhBMP-2-induced group and siSmad4 4 ng/ml rhBMP-2-induced groups
were then induced with 4 ng/ml rhBMP-2 for 24 h. Cells in each group
were incubated with ﬂuorophore-conjugated CD44 or CD24 antibodies for
30 min on ice. They were then washed with HBSS, and ﬂuorescent signals
were measured by the FACSCalibur ﬂow cytometer (Becton Dickinson, San
Jose, CA, USA).
Western blot
Proteins were extracted using the Nuclear and Cytoplasmic Extraction
Reagents kit (Thermo Fisher Scientiﬁc), according to the manufacturer’s
protocol. Equal amounts of protein (50 μg) were subjected to sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and
western blotting. Membranes were incubated overnight at 4 °C with
primary antibodies against Rb (Cell Signaling Technology, Danvers, MA,
USA), p-Rb (Ser807/811, Cell Signaling Technology), CD44 (Cell Signaling
Technology), p-AKT (Ser473, Cell Signaling Technology), p-ATK (Thr308, Cell
Signaling Technology), Histone3 (Cell Signaling Technology), AKT (Cell
Signaling Technology) and β-actin (Proteintech Group, Rosemont, IL, USA).
Membranes were washed in TBS-Tween, and were incubated with anti-
mouse secondary antibodies at a dilution of 1:8000 for 1 h. Immunor-
eactive bands were visualized using an enhanced chemiluminescence
reaction kit (Thermo Fisher Scientiﬁc), and were exposed on X-ray ﬁlms
(Kodak, Rochester, NY, USA).
Immunocytochemistry
MCF-7 cells grown on cover slips were washed twice with PBS, and then
ﬁxed with 4% paraformaldehyde for 15 min. They were then incubated
with 200 μl of 100 nM anti-CD44 (FITC) antibody (Sigma-Aldrich, St Louis,
Figure 6. BMP-2 induced EMT and breast cancer stemness through Rb and CD44 signaling. This diagram depicts the signaling pathway by
which rhBMP-2 is found to induce EMT and stemness of breast cancer cells through Rb and CD44 to contribute to breast cancer metastasis.
PI3K/AKT and Smad signaling pathway are implicated in the regulation of Rb and CD44 by rhBMP-2; cross-talk exists between Rb and CD44
signaling pathways.
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MO, USA) in the dark for 1 h. Cells were subsequently washed three times
in PBS to remove any unbound antibodies. Fluorescent images were
obtained with a Carl Zeiss LSM510 Meta Duo Scan laser scanning confocal
microscope.
Wound-healing assay
Breast cancer cells were seeded onto 12-well plates. When the cells
achieved 80% conﬂuence, they were serum-starved for 12 h in DMEM
supplemented with 1% FBS (1 mM thymidine). A wound was made across
the cell monolayer using the tip of a 200-μl pipette. The adherent
monolayer was washed twice with DMEM at 37 °C to remove the non-
adherent cells. Cells were then incubated with different concentrations
(0, 4 ng/ml) of rhBMP-2 for another 24 h. The open wound surface area and
the number of the cells in the area were photographed by an inverted
phase-contrast microscope (Olympus, Tokyo, Japan) and quantiﬁed with
ImagePro Plus software. All experiments were repeated three times.
Transwell migration experiment
Cell migration and invasion were examined by a transwell assay using
QCMTM 96-well plates (Chemicon, Temecula, CA, USA). After trypsinization,
100 μl 5 × 105 cells/ml were added to the upper surface of a 96-well plate,
150 μl of different concentrations (0, 4 ng/ml) of rhBMP-2 was plated and
used as a chemoattractant in the bottom well. After 24 h of incubation,
cells on the upper surface were removed by PBS and 150 μl dissociation
buffer was added into each well, and further incubated at 37 °C for 30 min.
CyQuant GR staining reagents (50 μl) were added to the mixture for 15 min
at room temperature. Samples were transferred to a new low ﬂuorescence
background 96-well plate, which was read using 480/520 nm
transmitted light.
Ubiquitination inhibition assay
MCF-7 cells were grown in complete DMEM with 10% FBS for 24 h, and
were serum-starved for 12 h with 1% FBS. The ubiquitin-activating enzyme
E1 inhibitor, PYR-41 (5 μM, Selleckchem, Houston, TX, USA) was added to
MCF-7 cells for 30 min, followed by rhBMP-2 (4 ng/ml) induction for 24 h
with 5% FBS. Proteins were extracted using the Nuclear and Cytoplasmic
Extraction Reagents (Thermo Fisher Scientiﬁc). Equal amounts of protein
(40 μg) were subjected to SDS-PAGE, and protein levels of Rb and p-Rb
(Ser807/811) were detected by western blots.
Statistics
Data are presented as mean± S.D.s derived from multiple experiments, as
indicated. Differences were assessed by the unpaired-Student’s t-test.
Po0.05 was considered to be statistically signiﬁcant (*Po0.05; **Po0.01;
***Po0.005).
Study approval
All animal procedures were approved by the Center for Animal at Jinan
University in accordance with the NIH Guide for the Care and Use of
Laboratory Animals (National Academies Press 2011) and the Animal
Welfare Act. The immunohistochemistry study used breast carcinoma
tissues was approved by the ethics committee of the First Afﬁliated
Hospital of Jinan University, and was carried out according to the IRB-
approved protocol. Each patient was properly informed and informed
consents were obtained from all patients prior to the study.
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